Literature DB >> 18452312

Nitric oxide regulation of MMP-9 activation and its relationship to modifications of the cysteine switch.

Sean M McCarthy1, Peter F Bove, Dwight E Matthews, Takaaki Akaike, Albert van der Vliet.   

Abstract

Matrix metalloproteases (MMPs) are Zn-containing endopeptidases involved in the degradation of extracellular matrix components and are typically secreted in a latent (pro-MMP) form and activated either by proteolytic or oxidative disruption of a conserved cysteine switch. Several recent studies have suggested that nitric oxide (NO) can contribute to the activation of MMPs, but the mechanisms involved are incompletely understood. We investigated the ability of NO to regulate the activation of (pro)MMP-9 using a variety of NO-donor compounds and characterized modifications of the cysteine switch using a synthetic peptide (PRCGVPDLGR) representing the cysteine switch domain of MMP-9. Among the NO-donors used, only S-nitrosocysteine (SNOC) was found to be capable of modest activation of proMMP-9, but S-nitrosoglutathione (GSNO) or the NONOates, DEA-NO, SPER-NO, or DETA-NO, were ineffective. In fact, high concentrations of DETA-NO were found to inhibit MMP-9 activity, presumably by direct interaction with the active-site Zn (2+). Analysis of chemical modifications within the Cys-containing peptide, PRCGVPDLGR, revealed rapid and transient S-nitrosylation by SNOC and GSNO, and formation of mixed disulfides and dimerized peptide as major final products. Similarly, NONOates induced transient S-nitrosylation and primarily peptide dimerization. Coordination of the peptide Cys with a synthetic Zn (2+) complex, to more closely mimic the structure of the active site in proMMP-9, reduced peptide nitrosylation and oxidation by NONOates, but enhanced peptide nitrosylation by SNOC and GSNO. Collectively, our results demonstrate that NO is incapable of directly activating proMMP-9 and that S-nitrosylation of MMP-9 propeptide by NO-donors is unrelated to their ability to regulate MMP-9 activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452312      PMCID: PMC3030771          DOI: 10.1021/bi702496v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  Activation of tumor necrosis factor-alpha-converting enzyme-mediated ectodomain shedding by nitric oxide.

Authors:  Z Zhang; J K Kolls; P Oliver; D Good; P O Schwarzenberger; M S Joshi; J L Ponthier; J R Lancaster
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

Review 2.  Matrix metalloproteinases: a tail of a frog that became a prince.

Authors:  Constance E Brinckerhoff; Lynn M Matrisian
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

3.  Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate.

Authors:  Z Zhang; P Oliver; J R Lancaster; P O Schwarzenberger; M S Joshi; J Cork; J K Kolls
Journal:  FASEB J       Date:  2000-12-08       Impact factor: 5.191

Review 4.  S-Nitrosothiol measurements in biological systems.

Authors:  Andrew Gow; Allan Doctor; Joan Mannick; Benjamin Gaston
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-25       Impact factor: 3.205

5.  Nitric oxide-induced changes in intracellular zinc homeostasis are mediated by metallothionein/thionein.

Authors:  Claudette M St Croix; K J Wasserloos; K E Dineley; I J Reynolds; E S Levitan; B R Pitt
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-02       Impact factor: 5.464

6.  Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation.

Authors:  T Okamoto; T Akaike; T Sawa; Y Miyamoto; A van der Vliet; H Maeda
Journal:  J Biol Chem       Date:  2001-06-06       Impact factor: 5.157

7.  Glutathione, lactobionate, and histidine: cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions.

Authors:  G A Upadhya; S M Strasberg
Journal:  Hepatology       Date:  2000-05       Impact factor: 17.425

8.  Decomposition of S-nitrosocysteine via S- to N-transnitrosation.

Authors:  Lisa A Peterson; Tanja Wagener; Helmut Sies; Wilhelm Stahl
Journal:  Chem Res Toxicol       Date:  2007-04-18       Impact factor: 3.739

9.  Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase.

Authors:  X Fu; S Y Kassim; W C Parks; J W Heinecke
Journal:  J Biol Chem       Date:  2001-08-30       Impact factor: 5.157

10.  Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways.

Authors:  Lisa A Ridnour; Alisha N Windhausen; Jeffrey S Isenberg; Nolan Yeung; Douglas D Thomas; Michael P Vitek; David D Roberts; David A Wink
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

View more
  22 in total

Review 1.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

Review 2.  Protein S-nitrosylation: role for nitric oxide signaling in neuronal death.

Authors:  Neelam Shahani; Akira Sawa
Journal:  Biochim Biophys Acta       Date:  2011-07-23

3.  The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction.

Authors:  Rachel A Schmidt; Craig N Morrell; Frederick S Ling; Preya Simlote; Genaro Fernandez; David Q Rich; David Adler; Joe Gervase; Scott J Cameron
Journal:  Transl Res       Date:  2017-12-02       Impact factor: 7.012

4.  Potential role of intermedin/adrenomedullin 2 in early embryonic development in rats.

Authors:  Madhu Chauhan; Rebekah Elkins; Meena Balakrishnan; Chandra Yallampalli
Journal:  Regul Pept       Date:  2011-06-02

Review 5.  Fetal programming and early identification of newborns at high risk of free radical-mediated diseases.

Authors:  Serafina Perrone; Antonino Santacroce; Anna Picardi; Giuseppe Buonocore
Journal:  World J Clin Pediatr       Date:  2016-05-08

6.  Electrophilic fatty acids regulate matrix metalloproteinase activity and expression.

Authors:  Gustavo Bonacci; Francisco J Schopfer; Carlos I Batthyany; Tanja K Rudolph; Volker Rudolph; Nicholas K H Khoo; Eric E Kelley; Bruce A Freeman
Journal:  J Biol Chem       Date:  2011-03-15       Impact factor: 5.157

Review 7.  Thioredoxin 1-mediated post-translational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies.

Authors:  Changgong Wu; Andrew M Parrott; Cexiong Fu; Tong Liu; Stefano M Marino; Vadim N Gladyshev; Mohit R Jain; Ahmet T Baykal; Qing Li; Shinichi Oka; Junichi Sadoshima; Annie Beuve; William J Simmons; Hong Li
Journal:  Antioxid Redox Signal       Date:  2011-06-08       Impact factor: 8.401

8.  Hemoglobin-induced nitric oxide synthase overexpression and nitric oxide production contribute to blood-brain barrier disruption in the rat.

Authors:  Shuo Yang; Yizhao Chen; Xinqing Deng; Weiping Jiang; Bing Li; Zhenghao Fu; Mouxuan Du; Rui Ding
Journal:  J Mol Neurosci       Date:  2013-03-15       Impact factor: 3.444

9.  Broad regulation of matrix and adhesion molecules in THP-1 human macrophages by nitroglycerin.

Authors:  Anu Shilpa Krishnatry; Daniel A Brazeau; Ho-Leung Fung
Journal:  Nitric Oxide       Date:  2009-10-15       Impact factor: 4.427

10.  Role of sulfiredoxin as a peroxiredoxin-2 denitrosylase in human iPSC-derived dopaminergic neurons.

Authors:  Carmen R Sunico; Abdullah Sultan; Tomohiro Nakamura; Nima Dolatabadi; James Parker; Bing Shan; Xuemei Han; John R Yates; Eliezer Masliah; Rajesh Ambasudhan; Nobuki Nakanishi; Stuart A Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.